107 related articles for article (PubMed ID: 7389256)
1. Kinetics and metabolism of intramuscular neostigmine in myasthenia gravis.
Somani SM; Chan K; Dehghan A; Calvey TN
Clin Pharmacol Ther; 1980 Jul; 28(1):64-8. PubMed ID: 7389256
[TBL] [Abstract][Full Text] [Related]
2. Metabolism and exretion of 3-hydroxyphenyltrimethylammonium and neostigmine.
Husain MA; Roberts JB; Thomas BH; Wilson A
Br J Pharmacol; 1969 Feb; 35(2):344-50. PubMed ID: 5774048
[TBL] [Abstract][Full Text] [Related]
3. Determination of neostigmine and pyridostigmine in the urine of patients with myasthenia gravis.
NOWELL PT; SCOTT CA; WILSON A
Br J Pharmacol Chemother; 1962 Jun; 18(3):617-24. PubMed ID: 14480648
[TBL] [Abstract][Full Text] [Related]
4. The pharmacokinetics of neostigmine and 3-hydroxyphenyltrimethyl- ammonium in the rat: dose-dependent effects after portal vein administration.
Barber HE; Bourne GR
Br J Pharmacol; 1974 Dec; 52(4):567-77. PubMed ID: 4455331
[TBL] [Abstract][Full Text] [Related]
5. Clinical pharmacokinetics of cholinesterase inhibitors.
Aquilonius SM; Hartvig P
Clin Pharmacokinet; 1986; 11(3):236-49. PubMed ID: 3524957
[TBL] [Abstract][Full Text] [Related]
6. Clinical pharmacology of pyridostigmine and neostigmine in patients with myasthenia gravis.
Aquilonius SM; Eckernäs SA; Hartvig P; Lindström B; Osterman PO; Stålberg E
J Neurol Neurosurg Psychiatry; 1983 Oct; 46(10):929-35. PubMed ID: 6644317
[TBL] [Abstract][Full Text] [Related]
7. Plasma clearance of neostigmine and pyridostigmine in the dog.
Baker PR; Calvey TN; Chan K; Macnee CM; Taylor K
Br J Pharmacol; 1978 Jul; 63(3):509-12. PubMed ID: 667495
[TBL] [Abstract][Full Text] [Related]
8. The effect of neostigmine on pyridostigmine bioavailability in myasthenic patients after oral administration.
Chan K; Davison SC; Dehghan A; Hyman N
Methods Find Exp Clin Pharmacol; 1981; 3(5):291-6. PubMed ID: 7329157
[TBL] [Abstract][Full Text] [Related]
9. Myasthenia gravis: report of a case with exophthalmos, without hyperthyroidism, relieved by neostigmine.
HATCH HA
N Engl J Med; 1952 May; 246(22):856-8. PubMed ID: 14929332
[No Abstract] [Full Text] [Related]
10. Pharmacokinetics and pharmacological effects of neostigmine in man.
Calvey TN; Wareing M; Williams NE; Chan K
Br J Clin Pharmacol; 1979 Feb; 7(2):149-55. PubMed ID: 216382
[TBL] [Abstract][Full Text] [Related]
11. Tetraethyl pyrophosphate in the myasthenia gravis.
NOVOTA OJ
Mo Med; 1952 Feb; 49(2):133-4. PubMed ID: 14938938
[No Abstract] [Full Text] [Related]
12. Hydrolysis of neostigmine by plasma cholinesterase.
NOWELL PT; SCOTT CA; WILSON A
Br J Pharmacol Chemother; 1962 Dec; 19(3):498-502. PubMed ID: 13939168
[TBL] [Abstract][Full Text] [Related]
13. Oral neostigmine and lymphatic absorption in a myasthenia gravis patient on continuous ambulatory peritoneal dialysis (CAPD).
Chan PC; Tam SC; Cheng IK
Perit Dial Int; 1990; 10(1):93-6. PubMed ID: 2085592
[TBL] [Abstract][Full Text] [Related]
14. Disposition kinetics of ethambutol in man.
Lee CS; Brater DC; Gambertoglio JG; Benet LZ
J Pharmacokinet Biopharm; 1980 Aug; 8(4):335-46. PubMed ID: 7431225
[TBL] [Abstract][Full Text] [Related]
15. Effect of neostigmine, d-tubocurarine and clinical condition on evoked electromyogram from orbicularis oculi in myasthenia gravis.
Matsuoka K; Katsuda T
Folia Psychiatr Neurol Jpn; 1968; 22(4):325-31. PubMed ID: 5756544
[No Abstract] [Full Text] [Related]
16. The simultaneous monitoring of plasma levels of neostigmine and pyridostigmine in man.
Davison SC; Hyman N; Prentis RA; Dehghan A; Chan K
Methods Find Exp Clin Pharmacol; 1980 Apr; 2(2):77-82. PubMed ID: 7339332
[TBL] [Abstract][Full Text] [Related]
17. Neostigmine-responsive weakness in the dog, similar to myasthenia gravis.
Lorenz MD; DeLahunta A; Alstrom DH
J Am Vet Med Assoc; 1972 Oct; 161(7):795-800. PubMed ID: 5074261
[No Abstract] [Full Text] [Related]
18. An investigation of the metabolism of neostigmine in patients with myasthenia gravis.
SCOTT CA; NOWELL PT; WILSON A
J Pharm Pharmacol; 1962 Dec; 14(Suppl)():31T-33T. PubMed ID: 13992512
[No Abstract] [Full Text] [Related]
19. The relationship between the pharmacokinetics, cholinesterase inhibition and facilitation of twitch tension of the quaternary ammonium anticholinesterase drugs, neostigmine, pyridostigmine, edrophonium and 3-hydroxyphenyltrimethylammonium.
Barber HE; Calvey TN; Muir KT
Br J Pharmacol; 1979 Aug; 66(4):525-30. PubMed ID: 223706
[TBL] [Abstract][Full Text] [Related]
20. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
